Long-term Outcome After Doxorubicin and Ifosfamide Overdose in a Patient With Osteosarcoma and BARD1 Mutation

Malvi Savani, Keith M Skubitz

Research output: Contribution to journalArticlepeer-review

1 Scopus citations

Abstract

Current treatment of high-grade osteosarcoma consists of preoperative chemotherapy, typically using some combination of doxorubicin, cisplatin, ifosfamide, and/or high-dose methotrexate followed by surgical resection. In this report, we present a case of a 21-year-old woman with high-grade osteosarcoma of the chest wall who received 5 times the planned dose of doxorubin and 4 times the planned dose of ifosfamide. She survived this chemotherapy overdose after administration of dimethyl sulfoxide and phenobarbital. Despite the administration of 5 times the proposed dose of doxorubicin, the patient survived without cardiotoxicity, and later delivered a normal baby. Although there are many studies evaluating treatment for chemotherapy regimen-related toxicity, sparse data exist with respect to chemotherapy overdose and the appropriate course of action. This case further confirms the lower cardiotoxicity of continuous intravenous infusion of doxorubicin and provides support for the use of dimethyl sulfoxide in the prevention of toxicity in chemotherapy overdose.

Original languageEnglish (US)
Pages (from-to)E94-E96
JournalJournal of pediatric hematology/oncology
Volume41
Issue number2
DOIs
StatePublished - Mar 1 2019

Keywords

  • BARD1
  • DMSO
  • chemotherapy overdose
  • doxorubicin
  • ifosfamide
  • osteosarcoma
  • toxicity

PubMed: MeSH publication types

  • Case Reports
  • Journal Article

Fingerprint Dive into the research topics of 'Long-term Outcome After Doxorubicin and Ifosfamide Overdose in a Patient With Osteosarcoma and BARD1 Mutation'. Together they form a unique fingerprint.

Cite this